Cost and efficacy of dissection devices in extended and parenchyma preserving liver resection: a prospective randomised trial

Submission date	Recruitment status No longer recruiting	Prospectively registered		
01/07/2008		☐ Protocol		
Registration date	Overall study status	Statistical analysis plan		
28/08/2008	Completed	[X] Results		
Last Edited	Condition category	[] Individual participant data		
30/06/2009	Cancer			

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Prof Martin K Schilling

Contact details

Department of General-, Visceral-, Vascular- and Paediatric Surgery University of Saarland Homburg/Saar Germany 66421

Additional identifiers

Protocol serial number N/A

Study information

Scientific Title

Acronym

LDD (Liver Dissection Devices)

Study objectives

Evaluate the surgical safety and the costs of different commercially available liver dissection devices.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Ethics approval received from the local Ethical Committee of the University of the Saarland in March 2005 (ref: 47/05)

Study design

Single-centre, randomised, single-blind study

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Primary or secondary hepatic malignacy

Interventions

Liver resection with three different liver resection (dissection) devices:

- 1. Selector® (Erbe, Tübingen, Germany)
- 2. Helix HydroJet® (Erbe, Tübingen, Germany)
- 3. Dissecting Sealer 3.0® (TissueLink Medical, Dover, NH, USA)

Total duration of follow-up in all treatment arms was until discharge from hospital, no further follow up was performed.

Intervention Type

Device

Phase

Not Specified

Primary outcome(s)

- 1. Blood loss
- 2. Intraoperative and postoperative blood transfusions
- 3. Dissection time
- 4. Resection area
- 5. Dissection speed
- 6. Blood loss per dissected area
- 7. Post-operative International Normalised Ratio (INR)
- 8. Post-operative partial thromboplastin time (PTT)
- 9. Post-operative bilirubin levels
- 10. Morbidity (bleeding, bile fistula, cholangitis, liver abscess, pleura effusion, pneumonia,

cardiac complications)

- 11. Intensive Care Unit (ICU) stay
- 12. Hospital stay

Primary and secondary outcomes were measured during the hospital stay.

Key secondary outcome(s))

- 1. Mounting time
- 2. Costs of devices (system costs)
- 3. Maintenance costs
- 4. Costs of additional haemostyptic items
- 5. Costs of staplers and magazines

Primary and secondary outcomes were measured during the hospital stay.

Completion date

30/06/2005

Eligibility

Key inclusion criteria

All patients undergoing liver resection for primary or secondary hepatic malignancy of any age and gender.

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Not Specified

Sex

All

Key exclusion criteria

- 1. Cirrhosis or cholestasis (serum bilirubin greater than 25 mg/dl)
- 2. Prior chemotherapy (within 6 months) and multiple liver tumours

Date of first enrolment

01/09/2003

Date of final enrolment

30/06/2005

Locations

Countries of recruitment

Germany

Study participating centre

Department of General-, Visceral-, Vascular- and Paediatric Surgery

Homburg/Saar

Germany

66421

Sponsor information

Organisation

University of Saarland (Germany)

ROR

https://ror.org/01jdpyv68

Funder(s)

Funder type

Other

Funder Name

Investigator initiated and funded (Germany)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/06/2009		Yes	No